We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.71 | 64.82 | 65.53 | 64.33 | 65.51 | 7,822,721 | 01:00:00 |
From May 2019 to May 2024
By Kimberly Chin
Gilead Sciences Inc.'s (GILD) profit rose in the latest quarter due to favorable tax benefits and an increase in net gains from equity securities.
The biopharmaceutical company said its fourth-quarter net income was $2.7 billion, compared with $3 million a year earlier. On a GAAP basis, earnings were $2.12 a share for the quarter. Excluding special items, the company posted an adjusted profit of $1.30 a share. Analysts polled by FactSet were expecting adjusted earnings of $1.67 a share.
Total revenue rose to $5.88 billion from $5.8 billion. Analysts estimated $5.72 billion in revenue.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
February 04, 2020 16:33 ET (21:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
